These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 37783677)
1. A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. Yang X; Smirnov A; Buonomo OC; Mauriello A; Shi Y; Bischof J; Woodsmith J; ; Melino G; Candi E; Bernassola F Cell Death Discov; 2023 Oct; 9(1):365. PubMed ID: 37783677 [TBL] [Abstract][Full Text] [Related]
2. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]. Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256 [No Abstract] [Full Text] [Related]
3. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. Jang BS; Han W; Kim IA Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471 [TBL] [Abstract][Full Text] [Related]
4. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
6. A comprehensive molecular characterization of a claudin-low luminal B breast tumor. Giovannini S; Smirnov A; Concetti L; Scimeca M; Mauriello A; Bischof J; Rovella V; Melino G; Buonomo CO; Candi E; Bernassola F Biol Direct; 2024 Aug; 19(1):66. PubMed ID: 39152485 [TBL] [Abstract][Full Text] [Related]
7. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report. Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032 [TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091 [TBL] [Abstract][Full Text] [Related]
9. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172 [TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178 [TBL] [Abstract][Full Text] [Related]
11. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102 [TBL] [Abstract][Full Text] [Related]
13. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient. Han Y; Rovella V; Smirnov A; Buonomo OC; Mauriello A; Perretta T; Shi Y; Woodmsith J; Bischof J; ; Melino G; Candi E; Bernassola F Cell Death Discov; 2023 Oct; 9(1):370. PubMed ID: 37813891 [TBL] [Abstract][Full Text] [Related]
14. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants. Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391 [TBL] [Abstract][Full Text] [Related]
15. Progress and challenges of immunotherapy in triple-negative breast cancer. Zhu Y; Zhu X; Tang C; Guan X; Zhang W Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474 [TBL] [Abstract][Full Text] [Related]
16. BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. Kang SY; Kim DG; Kim KM Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142641 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920 [TBL] [Abstract][Full Text] [Related]
19. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment. Song Y; Gu Y; Hu X; Wang M; He Q; Li Y Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613 [TBL] [Abstract][Full Text] [Related]
20. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR Front Oncol; 2023; 13():1235902. PubMed ID: 37637072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]